A phase 1/2a dose-finding study and biomarker assessment of oral lisavanbulin in patients with high-grade glioma or glioblastoma
Lisavanbulin is a prodrug of the microtubule-targeting agent avanbulin. Both avanbulin and lisavanbulin have demonstrated significant antitumor activity in several preclinical tumor models including glioblastoma. Previous human studies demonstrated that 48-h infusions of intravenous lisavanbulin wer...
Uloženo v:
| Vydáno v: | Cell reports. Medicine Ročník 6; číslo 6; s. 102165 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
Elsevier Inc
17.06.2025
Elsevier |
| Témata: | |
| ISSN: | 2666-3791, 2666-3791 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Lisavanbulin is a prodrug of the microtubule-targeting agent avanbulin. Both avanbulin and lisavanbulin have demonstrated significant antitumor activity in several preclinical tumor models including glioblastoma. Previous human studies demonstrated that 48-h infusions of intravenous lisavanbulin were well tolerated with preliminary activity in recurrent glioblastoma. The current phase 1/2a study evaluates the safety and tolerability of once-daily oral lisavanbulin in patients with solid tumors or recurrent glioblastoma or high-grade glioma. Lisavanbulin is associated with profound, durable responses in a subset of patients with recurrent refractory grade 4 astrocytoma or glioblastoma. We present here the clinical and translational results from this trial, including a description of a response-predictive molecular signature that warrants further exploration in these tumor types of significant unmet need. The study is registered at ClinicalTrials.gov (NCT02490800).
[Display omitted]
•Lisavanbulin is an orally dosed brain-penetrant mitotic spindle checkpoint inhibitor•Our study assesses lisavanbulin in refractory astrocytoma or glioblastoma•Lisavanbulin is tolerable in patients with these tumors•A subset of patients have durable efficacy responses to lisavanbulin
Lopez et al. report a phase 1/2a study evaluating once-daily oral lisavanbulin, a brain-penetrant microtubule-targeting agent in patients with solid tumors or recurrent high-grade glioma. Lisavanbulin is tolerable in these patients and is associated with profound, durable responses in a subset of patients with grade 4 astrocytoma or glioblastoma. |
|---|---|
| AbstractList | SummaryLisavanbulin is a prodrug of the microtubule-targeting agent avanbulin. Both avanbulin and lisavanbulin have demonstrated significant antitumor activity in several preclinical tumor models including glioblastoma. Previous human studies demonstrated that 48-h infusions of intravenous lisavanbulin were well tolerated with preliminary activity in recurrent glioblastoma. The current phase 1/2a study evaluates the safety and tolerability of once-daily oral lisavanbulin in patients with solid tumors or recurrent glioblastoma or high-grade glioma. Lisavanbulin is associated with profound, durable responses in a subset of patients with recurrent refractory grade 4 astrocytoma or glioblastoma. We present here the clinical and translational results from this trial, including a description of a response-predictive molecular signature that warrants further exploration in these tumor types of significant unmet need. The study is registered at ClinicalTrials.gov (NCT02490800). Lisavanbulin is a prodrug of the microtubule-targeting agent avanbulin. Both avanbulin and lisavanbulin have demonstrated significant antitumor activity in several preclinical tumor models including glioblastoma. Previous human studies demonstrated that 48-h infusions of intravenous lisavanbulin were well tolerated with preliminary activity in recurrent glioblastoma. The current phase 1/2a study evaluates the safety and tolerability of once-daily oral lisavanbulin in patients with solid tumors or recurrent glioblastoma or high-grade glioma. Lisavanbulin is associated with profound, durable responses in a subset of patients with recurrent refractory grade 4 astrocytoma or glioblastoma. We present here the clinical and translational results from this trial, including a description of a response-predictive molecular signature that warrants further exploration in these tumor types of significant unmet need. The study is registered at ClinicalTrials.gov (NCT02490800).Lisavanbulin is a prodrug of the microtubule-targeting agent avanbulin. Both avanbulin and lisavanbulin have demonstrated significant antitumor activity in several preclinical tumor models including glioblastoma. Previous human studies demonstrated that 48-h infusions of intravenous lisavanbulin were well tolerated with preliminary activity in recurrent glioblastoma. The current phase 1/2a study evaluates the safety and tolerability of once-daily oral lisavanbulin in patients with solid tumors or recurrent glioblastoma or high-grade glioma. Lisavanbulin is associated with profound, durable responses in a subset of patients with recurrent refractory grade 4 astrocytoma or glioblastoma. We present here the clinical and translational results from this trial, including a description of a response-predictive molecular signature that warrants further exploration in these tumor types of significant unmet need. The study is registered at ClinicalTrials.gov (NCT02490800). Lisavanbulin is a prodrug of the microtubule-targeting agent avanbulin. Both avanbulin and lisavanbulin have demonstrated significant antitumor activity in several preclinical tumor models including glioblastoma. Previous human studies demonstrated that 48-h infusions of intravenous lisavanbulin were well tolerated with preliminary activity in recurrent glioblastoma. The current phase 1/2a study evaluates the safety and tolerability of once-daily oral lisavanbulin in patients with solid tumors or recurrent glioblastoma or high-grade glioma. Lisavanbulin is associated with profound, durable responses in a subset of patients with recurrent refractory grade 4 astrocytoma or glioblastoma. We present here the clinical and translational results from this trial, including a description of a response-predictive molecular signature that warrants further exploration in these tumor types of significant unmet need. The study is registered at ClinicalTrials.gov (NCT02490800). [Display omitted] •Lisavanbulin is an orally dosed brain-penetrant mitotic spindle checkpoint inhibitor•Our study assesses lisavanbulin in refractory astrocytoma or glioblastoma•Lisavanbulin is tolerable in patients with these tumors•A subset of patients have durable efficacy responses to lisavanbulin Lopez et al. report a phase 1/2a study evaluating once-daily oral lisavanbulin, a brain-penetrant microtubule-targeting agent in patients with solid tumors or recurrent high-grade glioma. Lisavanbulin is tolerable in these patients and is associated with profound, durable responses in a subset of patients with grade 4 astrocytoma or glioblastoma. Lisavanbulin is a prodrug of the microtubule-targeting agent avanbulin. Both avanbulin and lisavanbulin have demonstrated significant antitumor activity in several preclinical tumor models including glioblastoma. Previous human studies demonstrated that 48-h infusions of intravenous lisavanbulin were well tolerated with preliminary activity in recurrent glioblastoma. The current phase 1/2a study evaluates the safety and tolerability of once-daily oral lisavanbulin in patients with solid tumors or recurrent glioblastoma or high-grade glioma. Lisavanbulin is associated with profound, durable responses in a subset of patients with recurrent refractory grade 4 astrocytoma or glioblastoma. We present here the clinical and translational results from this trial, including a description of a response-predictive molecular signature that warrants further exploration in these tumor types of significant unmet need. The study is registered at ClinicalTrials.gov (NCT02490800). Lisavanbulin is a prodrug of the microtubule-targeting agent avanbulin. Both avanbulin and lisavanbulin have demonstrated significant antitumor activity in several preclinical tumor models including glioblastoma. Previous human studies demonstrated that 48-h infusions of intravenous lisavanbulin were well tolerated with preliminary activity in recurrent glioblastoma. The current phase 1/2a study evaluates the safety and tolerability of once-daily oral lisavanbulin in patients with solid tumors or recurrent glioblastoma or high-grade glioma. Lisavanbulin is associated with profound, durable responses in a subset of patients with recurrent refractory grade 4 astrocytoma or glioblastoma. We present here the clinical and translational results from this trial, including a description of a response-predictive molecular signature that warrants further exploration in these tumor types of significant unmet need. The study is registered at ClinicalTrials.gov (NCT02490800). •Lisavanbulin is an orally dosed brain-penetrant mitotic spindle checkpoint inhibitor•Our study assesses lisavanbulin in refractory astrocytoma or glioblastoma•Lisavanbulin is tolerable in patients with these tumors•A subset of patients have durable efficacy responses to lisavanbulin Lopez et al. report a phase 1/2a study evaluating once-daily oral lisavanbulin, a brain-penetrant microtubule-targeting agent in patients with solid tumors or recurrent high-grade glioma. Lisavanbulin is tolerable in these patients and is associated with profound, durable responses in a subset of patients with grade 4 astrocytoma or glioblastoma. |
| ArticleNumber | 102165 |
| Author | Beebe, Kirk Tabatabai, Ghazaleh Haefliger, Simon Clement, Paul M. Steinbach, Joachim Hundsberger, Thomas Eisner, Joel Robert Kaindl, Thomas Läubli, Heinz Engelhardt, Marc Roth, Patrick Brazil, Lucy Wick, Antje Kristeleit, Rebecca Lopez, Juanita Suzanne Jeffry Evans, Thomas R. Wunderlich, Benjamin Lane, Heidi Plummer, Ruth Hau, Peter |
| Author_xml | – sequence: 1 givenname: Juanita Suzanne surname: Lopez fullname: Lopez, Juanita Suzanne email: juanita.lopez@icr.ac.uk organization: Drug Development Unit at the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research, Sutton, UK – sequence: 2 givenname: Simon surname: Haefliger fullname: Haefliger, Simon organization: Inselspital, Bern University Hospital, University of Bern, Department of Medical Oncology, Bern, Switzerland – sequence: 3 givenname: Ruth surname: Plummer fullname: Plummer, Ruth organization: Newcastle University and Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, UK – sequence: 4 givenname: Paul M. surname: Clement fullname: Clement, Paul M. organization: UZ Leuven - Department of Oncology, Leuven Cancer Institute - KU Leuven, Leuven, Belgium – sequence: 5 givenname: Thomas R. surname: Jeffry Evans fullname: Jeffry Evans, Thomas R. organization: University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK – sequence: 6 givenname: Heinz surname: Läubli fullname: Läubli, Heinz organization: Department of Oncology, University Hospital Basel, Basel, Switzerland – sequence: 7 givenname: Patrick surname: Roth fullname: Roth, Patrick organization: Department of Neurology, University Hospital Zurich and University of Zurich, Zürich, Switzerland – sequence: 8 givenname: Rebecca surname: Kristeleit fullname: Kristeleit, Rebecca organization: Guy’s and St Thomas’ NHS Foundation Trust and King’s College London, London, UK – sequence: 9 givenname: Lucy surname: Brazil fullname: Brazil, Lucy organization: Guy’s Hospital, Cancer Centre, London, UK – sequence: 10 givenname: Ghazaleh surname: Tabatabai fullname: Tabatabai, Ghazaleh organization: Department of Neurology & Interdisciplinary Neuro-Oncology, University Hospital Tübingen, Hertie Institute for Clinical Brain Research, Eberhard Karls Uninversity Tübingen, Tübingen, Germany – sequence: 11 givenname: Antje surname: Wick fullname: Wick, Antje organization: Neurology Department, University Clinic Universitätsklinikum, Heidelberg, Germany – sequence: 12 givenname: Benjamin surname: Wunderlich fullname: Wunderlich, Benjamin organization: Discovery Life Sciences Biomarker Services GmbH, Kassel, Germany – sequence: 13 givenname: Kirk surname: Beebe fullname: Beebe, Kirk organization: GeneCentric Therapeutics Inc., Durham, NC, USA – sequence: 14 givenname: Joel Robert surname: Eisner fullname: Eisner, Joel Robert organization: GeneCentric Therapeutics Inc., Durham, NC, USA – sequence: 15 givenname: Heidi surname: Lane fullname: Lane, Heidi organization: Basilea Pharmaceutica International Ltd, Allschwil, Switzerland – sequence: 16 givenname: Marc surname: Engelhardt fullname: Engelhardt, Marc organization: Basilea Pharmaceutica International Ltd, Allschwil, Switzerland – sequence: 17 givenname: Thomas orcidid: 0000-0001-9640-7937 surname: Kaindl fullname: Kaindl, Thomas email: thomas.kaindl@basilea.com organization: Basilea Pharmaceutica International Ltd, Allschwil, Switzerland – sequence: 18 givenname: Peter surname: Hau fullname: Hau, Peter organization: Wilhelm Sander NeuroOncology Unit and Department of Neurology - Neurooncology, University Hospital Regensburg, Regensburg, Germany – sequence: 19 givenname: Thomas surname: Hundsberger fullname: Hundsberger, Thomas organization: Department of Neurology and Medical Oncology, Cantonal Hospital St. Gallen, Sankt Gallen, Switzerland – sequence: 20 givenname: Joachim surname: Steinbach fullname: Steinbach, Joachim organization: Dr. Senckenberg Institute of Neurooncology, University Hospital, Goethe University Frankfurt, Frankfurt, Germany |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40532659$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFUstuFDEQHKEgEkJ-gAPykcts_Nh5IQSKIh6RInEgd6ttt2e9mbUXe2YhNz4dTzZECRIgWfKrqlrdVc-LAx88FsVLRheMsvp0vfih42bBKa_yA2d19aQ44nVdl6Lp2MGD82FxktKa0oxkrBX0WXG4pJXgddUdFT_PyHYFCQk75UBMSFha543zPUnjZG4IeEOUCxuI1xgJpIQpbdCPJFgSIgxkcAl24NU0OE_y2sLo8n8i3924IivXr8o-gkHSD7NMJt2e1ABpzPcXxVMLQ8KTu_24uPr44er8c3n55dPF-dllqauWjaVF2qgWumXdKKhAIbXcdNZwXlEjlkjzxkFb4GiFha5pWmgUVroTXc1QHBcXe1kTYC230eWGbmQAJ28fQuwlxNHpASVTQtlWLS12atmh6biiSremMbxtma6z1vu91nZSGzQ6d5sH8Uj08Y93K9mHnWSc01YwkRVe3ynE8G3CNMqNSxqHATyGKUnBORdVbpxl6KuHxe6r_LYwA_geoGNIKaK9hzAq56jItZyjIueoyH1UMuntnoR55DuHUSadXdNoXEQ95qG4f9Pf_UHX2X2nYbjGG0zrMEWfzZRMJi6p_DpncY5iNoty0c5dvfm7wP-q_wLmHfIF |
| Cites_doi | 10.1073/pnas.1300395110 10.1093/neuonc/noab162 10.1002/pbc.25329 10.1158/1535-7163.TARG-09-C233 10.1158/1538-7445.AM2014-831 10.18632/oncotarget.27374 10.1007/s10637-019-00850-z 10.1200/jco.2010.28.15_suppl.e13589 10.1016/j.radonc.2017.07.024 10.1038/s41416-020-1010-8 10.18632/oncotarget.2646 10.1038/s41571-020-00447-z 10.1158/1538-7445.AM10-4412 10.1158/1535-7163.MCT-13-0791 10.1242/jcs.062414 10.1016/j.jmb.2014.02.005 10.1007/s10637-023-01336-9 10.1016/S0959-8049(12)72219-0 10.1158/1535-7163.MCT-16-0252 10.1158/1538-7445.AM2011-1347 10.1093/neuonc/noaa106 |
| ContentType | Journal Article |
| Copyright | 2025 The Author(s) The Author(s) Copyright © 2025 The Author(s). Published by Elsevier Inc. All rights reserved. 2025 The Author(s) 2025 |
| Copyright_xml | – notice: 2025 The Author(s) – notice: The Author(s) – notice: Copyright © 2025 The Author(s). Published by Elsevier Inc. All rights reserved. – notice: 2025 The Author(s) 2025 |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.1016/j.xcrm.2025.102165 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2666-3791 |
| EndPage | 102165 |
| ExternalDocumentID | oai_doaj_org_article_1b3bf8b4fe9b49ed92b0bc8d7d2881c6 PMC12208313 40532659 10_1016_j_xcrm_2025_102165 S2666379125002381 1_s2_0_S2666379125002381 |
| Genre | Clinical Trial, Phase II Journal Article Clinical Trial, Phase I |
| GroupedDBID | .1- .FO 0R~ 53G AAEDW AALRI AAMRU AAXUO AAYWO ACVFH ADCNI ADVLN AEUPX AFPUW AFRHN AIGII AITUG AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ APXCP EBS FDB GROUPED_DOAJ M41 M~E OK1 ROL RPM Z5R 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c581t-fe07b8a9467ba5abe0f2d9fd2250d34e050d2acfa2ef3fa9778a7be5c93961e3 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 0 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001515909400002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2666-3791 |
| IngestDate | Mon Dec 01 19:30:13 EST 2025 Tue Sep 30 17:02:32 EDT 2025 Wed Jul 02 02:30:54 EDT 2025 Thu Jul 03 03:34:20 EDT 2025 Wed Nov 12 18:33:12 EST 2025 Sat Jul 19 17:10:41 EDT 2025 Sat Jul 12 02:44:28 EDT 2025 Tue Aug 26 19:32:32 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Keywords | glioma glioblastoma lisavanbulin astrocytoma |
| Language | English |
| License | This is an open access article under the CC BY-NC-ND license. Copyright © 2025 The Author(s). Published by Elsevier Inc. All rights reserved. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c581t-fe07b8a9467ba5abe0f2d9fd2250d34e050d2acfa2ef3fa9778a7be5c93961e3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Lead contact |
| ORCID | 0000-0001-9640-7937 |
| OpenAccessLink | https://doaj.org/article/1b3bf8b4fe9b49ed92b0bc8d7d2881c6 |
| PMID | 40532659 |
| PQID | 3222355811 |
| PQPubID | 23479 |
| PageCount | 1 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_1b3bf8b4fe9b49ed92b0bc8d7d2881c6 pubmedcentral_primary_oai_pubmedcentral_nih_gov_12208313 proquest_miscellaneous_3222355811 pubmed_primary_40532659 crossref_primary_10_1016_j_xcrm_2025_102165 elsevier_sciencedirect_doi_10_1016_j_xcrm_2025_102165 elsevier_clinicalkeyesjournals_1_s2_0_S2666379125002381 elsevier_clinicalkey_doi_10_1016_j_xcrm_2025_102165 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-06-17 |
| PublicationDateYYYYMMDD | 2025-06-17 |
| PublicationDate_xml | – month: 06 year: 2025 text: 2025-06-17 day: 17 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Cell reports. Medicine |
| PublicationTitleAlternate | Cell Rep Med |
| PublicationYear | 2025 |
| Publisher | Elsevier Inc Elsevier |
| Publisher_xml | – name: Elsevier Inc – name: Elsevier |
| References | Estève, Honoré, McKay, Bachmann, Lane, Braguer (bib3) 2010; 28 Wen, Weller, Lee, Alexander, Barnholtz-Sloan, Barthel, Batchelor, Bindra, Chang, Chiocca (bib23) 2020; 22 Bergès, Tchoghandjian, Sergé, Honoré, Figarella-Branger, Bachmann, Lane, Braguer (bib6) 2020; 11 Sharma, Broggini-Tenzer, Vuong, Messikommer, Nytko, Guckenberger, Bachmann, Lane, Pruschy (bib12) 2017; 124 Sharma, Broggini-Tenzer, Nytko-Karouzakis, Guckenberger, Bachmann, Lane, Pruschy (bib11) 2017; 193 Bachmann, Lane (bib13) 2012; 48 Joerger, Hundsberger, Haefliger, von Moos, Hottinger, Kaindl, Engelhardt, Marszewska, Lane, Roth, Stathis (bib20) 2023; 41 Kolb, Gorlick, Keir, Maris, Kang, Reynolds, Lock, Carol, Wu, Kurmasheva (bib8) 2015; 62 Foster-Gross, Bachmann, McSheehy, Lane (bib7) 2018; 103 Mohan, Katrukha, Doodhi, Smal, Meijering, Kapitein, Steinmetz, Akhmanova (bib17) 2013; 110 Burgenske, Talele, Pokorny, Mladek, Bakken, Carlson, Schroeder, He, Hu, Gampa (bib10) 2022; 24 Akhmanova, Steinmetz (bib15) 2010; 123 Bergès, Tchoghandjian, Honoré, Estève, Figarella-Branger, Bachmann, Lane, Braguer (bib5) 2016; 15 Pohlmann, Bachmann, Schmitt-Hoffmann, Gebhardt, Spickermann, Nuoffer, Biringer, O'Reilly, Pruschy, Lane (bib19) 2011; 71 Bachmann, Burger, Duran, Sikic, Lane (bib4) 2014; 74 Weller, van den Bent, Preusser, Le Rhun, Tonn, Minniti, Bendszus, Balana, Chinot, Dirven (bib24) 2021; 18 Holdhoff, Ye, Strowd, Nabors, Walbert, Lieberman, Bagley, Fiveash, Fisher, Desideri (bib22) 2024; 6 Lane, McSheehy, Bachmann (bib9) 2018; 103 Schmitt-Hoffmann, Klauer, Gebhardt, Fullhardt, Brendle, Hardgreaves, Schlaefle, Bucher, Spickermann, Defoin (bib14) 2009; 8 Duran, Lane, Bachmann, Sikic (bib2) 2010; 70 Kristeleit, Evans, Molife, Tunariu, Shaw, Slater, Haris, Brown, Forster, Diamantis (bib18) 2020; 123 Berges, Baeza-Kallee, Tabouret, Chinot, Petit, Kruczynski, Figarella-Branger, Honore, Braguer (bib16) 2014; 5 Mukhtar, Adhami, Mukhtar, Adhami, Mukhtar (bib25) 2014; 13 Prota, Danel, Bachmann, Bargsten, Buey, Pohlmann, Reinelt, Lane, Steinmetz (bib1) 2014; 426 Joerger, Stathis, Metaxas, Hess, Mantiero, Mark, Volden, Kaindl, Engelhardt, Larger (bib21) 2020; 38 Foster-Gross (10.1016/j.xcrm.2025.102165_bib7) 2018; 103 Berges (10.1016/j.xcrm.2025.102165_bib16) 2014; 5 Pohlmann (10.1016/j.xcrm.2025.102165_bib19) 2011; 71 Weller (10.1016/j.xcrm.2025.102165_bib24) 2021; 18 Estève (10.1016/j.xcrm.2025.102165_bib3) 2010; 28 Lane (10.1016/j.xcrm.2025.102165_bib9) 2018; 103 Akhmanova (10.1016/j.xcrm.2025.102165_bib15) 2010; 123 Duran (10.1016/j.xcrm.2025.102165_bib2) 2010; 70 Wen (10.1016/j.xcrm.2025.102165_bib23) 2020; 22 Joerger (10.1016/j.xcrm.2025.102165_bib21) 2020; 38 Bachmann (10.1016/j.xcrm.2025.102165_bib4) 2014; 74 Bergès (10.1016/j.xcrm.2025.102165_bib6) 2020; 11 Schmitt-Hoffmann (10.1016/j.xcrm.2025.102165_bib14) 2009; 8 Mohan (10.1016/j.xcrm.2025.102165_bib17) 2013; 110 Kolb (10.1016/j.xcrm.2025.102165_bib8) 2015; 62 Bergès (10.1016/j.xcrm.2025.102165_bib5) 2016; 15 Sharma (10.1016/j.xcrm.2025.102165_bib12) 2017; 124 Holdhoff (10.1016/j.xcrm.2025.102165_bib22) 2024; 6 Joerger (10.1016/j.xcrm.2025.102165_bib20) 2023; 41 Burgenske (10.1016/j.xcrm.2025.102165_bib10) 2022; 24 Mukhtar (10.1016/j.xcrm.2025.102165_bib25) 2014; 13 Prota (10.1016/j.xcrm.2025.102165_bib1) 2014; 426 Sharma (10.1016/j.xcrm.2025.102165_bib11) 2017; 193 Bachmann (10.1016/j.xcrm.2025.102165_bib13) 2012; 48 Kristeleit (10.1016/j.xcrm.2025.102165_bib18) 2020; 123 |
| References_xml | – volume: 48 start-page: 128 year: 2012 ident: bib13 article-title: 421 Dual Mechanism of Action of the Novel Microtubule-targeting Drug BAL27862 (active Moiety of the Prodrug BAL101553): Targeting Tumor and Vascular Cells publication-title: Eur. J. Cancer – volume: 71 start-page: 1347 year: 2011 ident: bib19 article-title: Abstract 1347: BAL101553: An optimized prodrug of the microtubule destabilizer BAL27862 with superior antitumor activity publication-title: Cancer Res. – volume: 74 start-page: 831 year: 2014 ident: bib4 article-title: Abstract 831: BAL101553 (prodrug of BAL27862): A unique microtubule destabilizer active against drug refractory breast cancers alone and in combination with trastuzumab publication-title: Cancer Res. – volume: 124 start-page: 433 year: 2017 end-page: 438 ident: bib12 article-title: The novel microtubule targeting agent BAL101553 in combination with radiotherapy in treatment-refractory tumor models publication-title: Radiother. Oncol. – volume: 193 start-page: 870 year: 2017 ident: bib11 article-title: The novel microtubule-destabilizing drug BAL101553 acts as radiosensitizing agent in treatment refractory tumor models publication-title: Strahlenther. Onkol. – volume: 22 start-page: 1073 year: 2020 end-page: 1113 ident: bib23 article-title: Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions publication-title: Neuro Oncol. – volume: 62 start-page: 1106 year: 2015 end-page: 1109 ident: bib8 article-title: Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program publication-title: Pediatr. Blood Cancer – volume: 38 start-page: 1067 year: 2020 end-page: 1076 ident: bib21 article-title: A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors publication-title: Invest. New Drugs – volume: 103 start-page: e8 year: 2018 ident: bib9 article-title: BAL101553, a novel microtubule-targeting tumor checkpoint controller, synergizes with gemcitabine providing cures in a PDX-pancreatic model publication-title: Eur. J. Cancer – volume: 123 start-page: 3415 year: 2010 end-page: 3419 ident: bib15 article-title: Microtubule +TIPs at a glance publication-title: J. Cell Sci. – volume: 11 start-page: 759 year: 2020 end-page: 774 ident: bib6 article-title: EB1-dependent long survival of glioblastoma-grafted mice with the oral tubulin-binder BAL101553 is associated with inhibition of tumor angiogenesis publication-title: Oncotarget – volume: 18 start-page: 170 year: 2021 end-page: 186 ident: bib24 article-title: EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood publication-title: Nat. Rev. Clin. Oncol. – volume: 110 start-page: 8900 year: 2013 end-page: 8905 ident: bib17 article-title: End-binding proteins sensitize microtubules to the action of microtubule-targeting agents publication-title: Proc. Natl. Acad. Sci. USA – volume: 24 start-page: 384 year: 2022 end-page: 395 ident: bib10 article-title: Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin—a novel tumor checkpoint controller targeting microtubules publication-title: Neuro Oncol. – volume: 123 start-page: 1360 year: 2020 end-page: 1369 ident: bib18 article-title: Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours publication-title: Br. J. Cancer – volume: 15 start-page: 2740 year: 2016 end-page: 2749 ident: bib5 article-title: The novel tubulin-binding checkpoint activator BAL101553 inhibits EB1-dependent migration and invasion and promotes differentiation of glioblastoma stem-like cells publication-title: Mol. Cancer Ther. – volume: 103 start-page: e6 year: 2018 ident: bib7 article-title: BAL101553, a novel microtubule-targeting tumor checkpoint controller, synergizes with gemcitabine providing cures in a PDX-pancreatic model publication-title: Eur. J. Cancer – volume: 5 start-page: 12769 year: 2014 end-page: 12787 ident: bib16 article-title: End-binding 1 protein overexpression correlates with glioblastoma progression and sensitizes to Vinca-alkaloids in vitro and in vivo publication-title: Oncotarget – volume: 28 start-page: e13589 year: 2010 ident: bib3 article-title: BAL27862: A unique microtubule-targeted agent that severs microtubules and overcomes multifactorial drug resistance publication-title: J. Clin. Oncol. – volume: 6 year: 2024 ident: bib22 article-title: Lisavanbulin (BAL101553), a novel microtubule inhibitor, plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastoma publication-title: Neurooncol. Adv. – volume: 13 start-page: 275 year: 2014 end-page: 284 ident: bib25 article-title: Targeting Microtubules by Natural Agents for Cancer Therapy publication-title: Mol. Cancer Ther. – volume: 426 start-page: 1848 year: 2014 end-page: 1860 ident: bib1 article-title: The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization publication-title: J. Mol. Biol. – volume: 8 start-page: C233 year: 2009 ident: bib14 article-title: BAL27862: A unique microtubule-targeted agent with a potential for the treatment of human brain tumors publication-title: Mol. Cancer Ther. – volume: 41 start-page: 267 year: 2023 end-page: 275 ident: bib20 article-title: Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study publication-title: Invest. New Drugs – volume: 70 start-page: 4412 year: 2010 ident: bib2 article-title: In vitro activity of the novel tubulin active agent BAL27862 in MDR1(+) and MDR1(-) human breast and ovarian cancer variants selected for resistance to taxanes publication-title: Cancer Res. – volume: 110 start-page: 8900 year: 2013 ident: 10.1016/j.xcrm.2025.102165_bib17 article-title: End-binding proteins sensitize microtubules to the action of microtubule-targeting agents publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.1300395110 – volume: 24 start-page: 384 year: 2022 ident: 10.1016/j.xcrm.2025.102165_bib10 article-title: Preclinical modeling in glioblastoma patient-derived xenograft (GBM PDX) xenografts to guide clinical development of lisavanbulin—a novel tumor checkpoint controller targeting microtubules publication-title: Neuro Oncol. doi: 10.1093/neuonc/noab162 – volume: 62 start-page: 1106 year: 2015 ident: 10.1016/j.xcrm.2025.102165_bib8 article-title: Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program publication-title: Pediatr. Blood Cancer doi: 10.1002/pbc.25329 – volume: 8 start-page: C233 year: 2009 ident: 10.1016/j.xcrm.2025.102165_bib14 article-title: BAL27862: A unique microtubule-targeted agent with a potential for the treatment of human brain tumors publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.TARG-09-C233 – volume: 74 start-page: 831 year: 2014 ident: 10.1016/j.xcrm.2025.102165_bib4 article-title: Abstract 831: BAL101553 (prodrug of BAL27862): A unique microtubule destabilizer active against drug refractory breast cancers alone and in combination with trastuzumab publication-title: Cancer Res. doi: 10.1158/1538-7445.AM2014-831 – volume: 11 start-page: 759 year: 2020 ident: 10.1016/j.xcrm.2025.102165_bib6 article-title: EB1-dependent long survival of glioblastoma-grafted mice with the oral tubulin-binder BAL101553 is associated with inhibition of tumor angiogenesis publication-title: Oncotarget doi: 10.18632/oncotarget.27374 – volume: 38 start-page: 1067 year: 2020 ident: 10.1016/j.xcrm.2025.102165_bib21 article-title: A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors publication-title: Invest. New Drugs doi: 10.1007/s10637-019-00850-z – volume: 28 start-page: e13589 year: 2010 ident: 10.1016/j.xcrm.2025.102165_bib3 article-title: BAL27862: A unique microtubule-targeted agent that severs microtubules and overcomes multifactorial drug resistance publication-title: J. Clin. Oncol. doi: 10.1200/jco.2010.28.15_suppl.e13589 – volume: 124 start-page: 433 year: 2017 ident: 10.1016/j.xcrm.2025.102165_bib12 article-title: The novel microtubule targeting agent BAL101553 in combination with radiotherapy in treatment-refractory tumor models publication-title: Radiother. Oncol. doi: 10.1016/j.radonc.2017.07.024 – volume: 123 start-page: 1360 year: 2020 ident: 10.1016/j.xcrm.2025.102165_bib18 article-title: Phase 1/2a trial of intravenous BAL101553, a novel controller of the spindle assembly checkpoint, in advanced solid tumours publication-title: Br. J. Cancer doi: 10.1038/s41416-020-1010-8 – volume: 5 start-page: 12769 year: 2014 ident: 10.1016/j.xcrm.2025.102165_bib16 article-title: End-binding 1 protein overexpression correlates with glioblastoma progression and sensitizes to Vinca-alkaloids in vitro and in vivo publication-title: Oncotarget doi: 10.18632/oncotarget.2646 – volume: 18 start-page: 170 year: 2021 ident: 10.1016/j.xcrm.2025.102165_bib24 article-title: EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood publication-title: Nat. Rev. Clin. Oncol. doi: 10.1038/s41571-020-00447-z – volume: 70 start-page: 4412 year: 2010 ident: 10.1016/j.xcrm.2025.102165_bib2 article-title: In vitro activity of the novel tubulin active agent BAL27862 in MDR1(+) and MDR1(-) human breast and ovarian cancer variants selected for resistance to taxanes publication-title: Cancer Res. doi: 10.1158/1538-7445.AM10-4412 – volume: 13 start-page: 275 year: 2014 ident: 10.1016/j.xcrm.2025.102165_bib25 article-title: Targeting Microtubules by Natural Agents for Cancer Therapy publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-13-0791 – volume: 103 start-page: e6 year: 2018 ident: 10.1016/j.xcrm.2025.102165_bib7 article-title: BAL101553, a novel microtubule-targeting tumor checkpoint controller, synergizes with gemcitabine providing cures in a PDX-pancreatic model publication-title: Eur. J. Cancer – volume: 193 start-page: 870 year: 2017 ident: 10.1016/j.xcrm.2025.102165_bib11 article-title: The novel microtubule-destabilizing drug BAL101553 acts as radiosensitizing agent in treatment refractory tumor models publication-title: Strahlenther. Onkol. – volume: 103 start-page: e8 year: 2018 ident: 10.1016/j.xcrm.2025.102165_bib9 article-title: BAL101553, a novel microtubule-targeting tumor checkpoint controller, synergizes with gemcitabine providing cures in a PDX-pancreatic model publication-title: Eur. J. Cancer – volume: 123 start-page: 3415 year: 2010 ident: 10.1016/j.xcrm.2025.102165_bib15 article-title: Microtubule +TIPs at a glance publication-title: J. Cell Sci. doi: 10.1242/jcs.062414 – volume: 426 start-page: 1848 year: 2014 ident: 10.1016/j.xcrm.2025.102165_bib1 article-title: The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization publication-title: J. Mol. Biol. doi: 10.1016/j.jmb.2014.02.005 – volume: 41 start-page: 267 year: 2023 ident: 10.1016/j.xcrm.2025.102165_bib20 article-title: Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study publication-title: Invest. New Drugs doi: 10.1007/s10637-023-01336-9 – volume: 48 start-page: 128 year: 2012 ident: 10.1016/j.xcrm.2025.102165_bib13 article-title: 421 Dual Mechanism of Action of the Novel Microtubule-targeting Drug BAL27862 (active Moiety of the Prodrug BAL101553): Targeting Tumor and Vascular Cells publication-title: Eur. J. Cancer doi: 10.1016/S0959-8049(12)72219-0 – volume: 15 start-page: 2740 year: 2016 ident: 10.1016/j.xcrm.2025.102165_bib5 article-title: The novel tubulin-binding checkpoint activator BAL101553 inhibits EB1-dependent migration and invasion and promotes differentiation of glioblastoma stem-like cells publication-title: Mol. Cancer Ther. doi: 10.1158/1535-7163.MCT-16-0252 – volume: 71 start-page: 1347 year: 2011 ident: 10.1016/j.xcrm.2025.102165_bib19 article-title: Abstract 1347: BAL101553: An optimized prodrug of the microtubule destabilizer BAL27862 with superior antitumor activity publication-title: Cancer Res. doi: 10.1158/1538-7445.AM2011-1347 – volume: 22 start-page: 1073 year: 2020 ident: 10.1016/j.xcrm.2025.102165_bib23 article-title: Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions publication-title: Neuro Oncol. doi: 10.1093/neuonc/noaa106 – volume: 6 year: 2024 ident: 10.1016/j.xcrm.2025.102165_bib22 article-title: Lisavanbulin (BAL101553), a novel microtubule inhibitor, plus radiation in patients with newly diagnosed, MGMT promoter unmethylated glioblastoma publication-title: Neurooncol. Adv. |
| SSID | ssj0002511830 |
| Score | 2.2946804 |
| Snippet | Lisavanbulin is a prodrug of the microtubule-targeting agent avanbulin. Both avanbulin and lisavanbulin have demonstrated significant antitumor activity in... SummaryLisavanbulin is a prodrug of the microtubule-targeting agent avanbulin. Both avanbulin and lisavanbulin have demonstrated significant antitumor activity... |
| SourceID | doaj pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 102165 |
| SubjectTerms | Administration, Oral Adult Advanced Basic Science Aged Antineoplastic Agents - administration & dosage Antineoplastic Agents - therapeutic use astrocytoma Biomarkers, Tumor - metabolism Brain Neoplasms - drug therapy Brain Neoplasms - pathology Dose-Response Relationship, Drug Female glioblastoma Glioblastoma - drug therapy Glioblastoma - metabolism Glioblastoma - pathology glioma Glioma - drug therapy Glioma - metabolism Glioma - pathology Humans lisavanbulin Male Middle Aged Neoplasm Grading |
| Title | A phase 1/2a dose-finding study and biomarker assessment of oral lisavanbulin in patients with high-grade glioma or glioblastoma |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S2666379125002381 https://www.clinicalkey.es/playcontent/1-s2.0-S2666379125002381 https://dx.doi.org/10.1016/j.xcrm.2025.102165 https://www.ncbi.nlm.nih.gov/pubmed/40532659 https://www.proquest.com/docview/3222355811 https://pubmed.ncbi.nlm.nih.gov/PMC12208313 https://doaj.org/article/1b3bf8b4fe9b49ed92b0bc8d7d2881c6 |
| Volume | 6 |
| WOSCitedRecordID | wos001515909400002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2666-3791 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002511830 issn: 2666-3791 databaseCode: DOA dateStart: 20200101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2666-3791 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0002511830 issn: 2666-3791 databaseCode: M~E dateStart: 20200101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBZtKKWX0nfcR1Cht2JiSbYlH9OS0EtCoTnsTUjWaLMleIO9KT2V_PTMyN5lty3NpWDW-7Bke2ak-bya-YaxD0WJdlKDyl0oqrzUdZsbwMnQgfTBiBhC3aZiE_rszMxmzdetUl8UEzbSA4-COxRe-Wh8GaHxZQOhkb7wrQk6SGNEm8i2EfVsPUzRHJyAsyqmLJkxoOtn21PquayIrkCQN9nyRImwf8ch_Qk4f4-b3HJEJ0_Y4wlB8qPxyp-ye9A9Yw9PpzXy5-zmiF9doG_i4lA6HpYD5GlhupvzxCXLXRc4Zd1TYE7P3Yaaky8jp3x9frkYHAJsT0HqHLeJe3Xg9KctJ4LjfN67AHx-Sd1go_TOIxBf4ecX7Pzk-Pzzl3yqs5C3lRGrPEKhvXENzpneVc5DEWVoYsChXgRVQoE76droJEQVHSJG47SHqm1UUwtQL9let-xgn_GoC3BQa4h1jXpXzrW1SFV2HT6Hepexj2uR26uRTcOuw8y-W1KQJQXZUUEZ-0Ra2RxJTNjpC7QPO9mHvcs-MqbWOrXrZFOcHrGjxT9Prf_WCoZphA9W2EHawn5DgFMr3SBOHOFPxqpNywnEjODkzjO-XxucxRFOyzaug-X1YGktjEjwBfb9ajTAjUhKKuxRV03GzI5p7shs95ducZFYxIWUVGVOvf4fUn7DHtG9UAyd0G_Z3qq_hnfsQftjtRj6A3Zfz8xBGqH4evrr-BZSRET3 |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+phase+1%2F2a+dose-finding+study+and+biomarker+assessment+of+oral+lisavanbulin+in+patients+with+high-grade+glioma+or+glioblastoma&rft.jtitle=Cell+reports.+Medicine&rft.au=Juanita+Suzanne+Lopez&rft.au=Simon+Haefliger&rft.au=Ruth+Plummer&rft.au=Paul+M.+Clement&rft.date=2025-06-17&rft.pub=Elsevier&rft.eissn=2666-3791&rft.volume=6&rft.issue=6&rft.spage=102165&rft_id=info:doi/10.1016%2Fj.xcrm.2025.102165&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_1b3bf8b4fe9b49ed92b0bc8d7d2881c6 |
| thumbnail_m | http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F26663791%2FS2666379124X00075%2Fcov150h.gif |